Skip to content
PreclinicalResearch compoundModerate evidence

Centrophenoxine

Old anti-aging nootropic (meclofenoxate), supported mainly by animal studies and not proven in humans.

NootropicNootropicCholinergicAcetylcholineAcetylcholine

Pharmacology

ClassNootropic · Cholinergic · Acetylcholine
Primary targetAcetylcholine (DMAE/choline precursor)
Targets4 receptor targets
EvidenceModerate evidence
Affected systemsAcetylcholine

Contents

DETAILED OVERVIEW

What is Centrophenoxine?

Centrophenoxine (meclofenoxate, sold as Lucidril) is an old, so-called anti-aging nootropic, intended mainly to support the working of the aging brain. It is a prescription medicine in Hungary, Poland and the Czech Republic; in the United States it is not approved, but it is sold there as a dietary supplement.

When broken down in the body it releases a choline-like substance (DMAE), which partly serves as a raw material for acetylcholine, a brain messenger. The idea is that it reduces lipofuscin, the waste material that builds up in aging cells. Its evidence comes mainly from animal studies, for example learning tests in old mice, and it is not proven in humans. Headache, insomnia, restlessness and raised blood pressure can occur. It should be avoided in pregnancy and breastfeeding, and in epilepsy or a tendency to seizures.

Mechanism

Releases a choline-like substance (DMAE); antioxidant

Half-life

~2-4 h

Legal status

EU Rx (some countries)

Receptor profile

  • Acetylcholine (via DMAE/choline)Moderate
  • Lipofuscin (age pigment)Moderate
  • Phosphatidylcholine (membrane)Moderate
  • Antioxidant enzymesWeak

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Headache (from cholinergic activity, DMAE release)
  • Nausea, gastrointestinal discomfort
  • Insomnia, restlessness, hence morning dosing is advised
  • Irritability, muscle tension or twitching at higher doses
  • Dizziness, cholinergic overstimulation (excess DMAE-choline effect)
  • Blood pressure elevation or mild palpitations

Contraindications · 6

  • Pregnancy and breastfeeding (insufficient safety data)
  • Seizure susceptibility, epilepsy (avoid due to cholinergic stimulation)
  • Severe hypertension or agitated, restless states
  • Concurrent cholinergic agents (cholinesterase inhibitors, other DMAE/choline sources), risk of additive effect
  • Caution in impaired renal function (reduced clearance)
  • Prescription-only in Hungary, Poland, Czechia, medical supervision advised

Related Nootropics

Same therapeutic category

FAQ

FAQ

Centrophenoxine is an older "anti-aging" style nootropic thought to help clear built-up cellular waste (lipofuscin) from brain cells while also supplying choline. It's aimed mainly at supporting an aging brain, but most of the supporting evidence comes from animal studies (learning tests in older mice), with limited human data.

Telegram

Have a question about Centrophenoxine?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC12H16ClNO3
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.